MP0712, co-developed with strategic partner Orano Med, is evaluated in an ongoing Phase 1/2a trial in the US for the treatment of patients with small cell lung cancer (SCLC) and other DLL3-expressing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results